Aerovate Therapeutics Investor Relations Material
Latest events
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Aerovate Therapeutics Inc
Access all reports
Aerovate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for rare cardiopulmonary diseases. The company's lead product candidate is AV-101, a dry powder inhaled formulation of imatinib, designed to treat pulmonary arterial hypertension (PAH). This formulation aims to deliver the drug directly to the lungs, targeting the underlying disease mechanisms while minimizing systemic side effects. Aerovate Therapeutics is headquartered in Waltham, Massachusetts, and its shares are listed on the NASDAQ.
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
AVTE
Country
🇺🇸 United States